• Anthony Morlandt, M.D., D.D.S., FACS
    Dr. Morlandt was born and raised in Floresville, Texas and graduated from Baylor University. He completed his DDS magna cum laude at the University of Texas Health Sciences Center in San Antonio, Texas, and received his MD and internship and residency in Oral and Maxillofacial Surgery from the University of Alabama School of Medicine. Dr. Morlandt then went on to complete a fellowship in head and neck oncology and microsurgery at the University of Florida College of Medicine in Jacksonville, Florida. He returned to Birmingham where he currently serves as Chief of the Section of Oral Oncology within the Department of Oral and Maxillofacial Surgery at UAB Medicine and is a full time academic head and neck surgeon. He is Director of the Head and Neck Oncology Fellowship program at UAB. Dr. Morlandt is an Associate Scientist in the Cancer Chemoprevention Program with the UAB Comprehensive Cancer Center. In 2015, Dr. Morlandt received the AAOMS Faculty Educator Development Award and has been inducted into the American Head and Neck Society and is a Fellow of the American College of Surgeons. He is a Diplomate of the American Board of Oral and Maxillofacial Surgery.

    Dr. Morlandt specializes in oral oncology, head and neck microvascular surgery, and oral and maxillofacial surgery. He has authored several peer-reviewed scientific articles and textbook chapters on head and neck ablative and reconstructive surgery. He is particularly interested in helping doctors and their staff identify head and neck cancers and in optimizing patient outcomes following major head and neck surgery.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2022 Computer-Assisted Microvascular Free Flap Reconstruction and Implant Rehabilitation of the Maxilla—Treatment of a Rare Post-orthognathic ComplicationJournal of Maxillofacial and Oral Surgery.  21:82-87. 2022
    2021 Does Nodal Metastasis and Perineural Invasion Affect Local Control in Hyalinizing Clear Cell Carcinoma of the Oral Cavity? A Case Report with Long Term Follow-UpHead and Neck Pathology.  15:649-656. 2021
    2021 Fasciocutaneous Flaps for Refractory Intermediate Stage Osteoradionecrosis of the Mandible—Is It Time for a Shift in Management?Journal of oral surgery, anesthesia, and hospital dental service.  79:1156-1167. 2021
    2021 Does Supplemental Regional Anesthesia Decrease Length of Stay and Opioid Use for Patients Undergoing Head and Neck Microvascular Reconstruction?Journal of oral surgery, anesthesia, and hospital dental service.  79:712-721. 2021
    2020 Titanium Alloy Cutting Guides in Craniomaxillofacial Surgery—A Minimally Invasive Alternative to Synthetic Polymer GuidesJournal of oral surgery, anesthesia, and hospital dental service.  78:2080-2089. 2020
    2020 Fluorescently Labeled Cetuximab-IRDye800 for Guided Surgical Excision of Ameloblastoma: A Proof of Principle StudyJournal of oral surgery, anesthesia, and hospital dental service.  78:1736-1747. 2020
    2020 Zygomatic Implants for Restoration of Complex Nasal Defects – A Case Report and Outcome 2020
    2020 A case of dyskeratosis congenita with squamous cell carcinoma of the maxilla: A case report and review of the literatureOral and Maxillofacial Surgery Cases.  6. 2020
    2020 Surgical margins in oral cavity squamous cell carcinoma: Current practices and future directions 2020
    2018 Advancements in Maxillofacial Trauma: A Historical PerspectiveJournal of oral surgery, anesthesia, and hospital dental service.  76:2256-2270. 2018
    2017 Fluorescence Imaging for Cancer Screening and SurveillanceMolecular Imaging and Biology.  19:645-655. 2017
    2017 Reconstruction of midface defects with the osteocutaneous radial forearm flap: Evaluation of long term outcomes including patient reported quality of lifeMicrosurgery.  37:752-762. 2017
    2017 Retraction to: Worst Pattern Of Invasion and occult cervical metastases for oral squamous carcinoma: Update on impact of adjuvant rt for low-stage high-risk oral squamous cancer (Head & Neck, (2017), 10.1002/hed.24754) 2017
    2017 Effects of an Unlabeled Loading Dose on Tumor-Specific Uptake of a Fluorescently Labeled Antibody for Optical Surgical NavigationMolecular Imaging and Biology.  19:610-616. 2017
    2017 Characterizing the utility and limitations of repurposing an open-field optical imaging device for fluorescence-guided surgery in head and neck cancer patientsJournal of Nuclear Medicine.  58:246-251. 2017
    2017 Worst Pattern Of Invasion and occult cervical metastases for oral squamous carcinoma 2017
    2015 Early oral tongue squamous cell carcinoma sampling of margins from tumor bed and worse local controlJAMA Otolaryngology-Head and Neck Surgery.  141:1104-1110. 2015
    2015 Safety and tumor specificity of cetuximab-IRDye800 for surgical navigation in head and neck cancerClinical Cancer Research.  21:3658-3666. 2015
    2015 A ratiometric threshold for determining presence of cancer during fluorescence-guided surgery 2015
    2015 Procedure/Technique: Endocrine tumors of the neckAtlas of The Oral and Maxillofacial Surgery Clinics of North America.  23:39-47. 2015
    2013 Reconstruction of the Scalp, Calvarium, and Frontal SinusOral and Maxillofacial Surgery Clinics of North America.  25:105-129. 2013
    2013 Safety and efficacy of intra-articular infliximab therapy for treatment-resistant temporomandibular joint arthritis in children: A retrospective studyRheumatology.  52:554-559. 2013
    2007 The national student research group of the AADR - An introduction 2007
    2005 Tetracycline at subcytotoxic levels inhibits matrix metalloproteinase-2 and -9 but does not remove the smear layerJournal of Periodontology.  76:1129-1139. 2005


    Year Title Altmetric
    2019 Genetics of oral cancer.  97-103. 2019
    2015 Surgical Management of the Neck.  424-430. 2015

    Research Overview

  • -Adjunctive Pentoxifylline and tocopherol (PENTO) in the treatment of related osteonecrosis of the jaw (MRONJ): a prospective, randomized trial to evaluate a novel non-surgical treatment. (ClinicalTrials.gov Identifier: NCT03040778).
    -2011472- IR-Labeled Cetuximab for Optical Imaging of Odontogenic Neoplasms
    Sponsoring Agency: Oral and Maxillofacial Surgery Foundation. Awarded 2015
    -X080416005 – “Protein Expression in Squamous Cell Carcinoma of the Craniofacial Complex”
  • Education And Training

  • UAB Hospital, Internship
  • UAB Hospital, Internship
  • UAB Hospital, Residency
  • Shands Jacksonville Medical Center, Postdoctoral Fellowship
  • Doctor of Medicine, University of Alabama at Birmingham 2010
  • Doctor of Dental Surgery in Dentistry, University of Texas System : San Antonio 2007
  • Full Name

  • Anthony Morlandt